Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year

Eli Lilly is racing to market donanemab for Alzheimer's after Eisai and Biogen's drug for the disease, Leqembi, won FDA approval this month.

from Health and Science https://ift.tt/xOiqbGy
https://ift.tt/nQmDGkx
https://ift.tt/fexrVkN